580 related articles for article (PubMed ID: 33280239)
1. Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut-kidney axis.
Li L; Wei T; Liu S; Wang C; Zhao M; Feng Y; Ma L; Lu Y; Fu P; Liu J
J Cell Mol Med; 2021 Jan; 25(2):960-974. PubMed ID: 33280239
[TBL] [Abstract][Full Text] [Related]
2. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/β-catenin signaling pathway in diabetic kidney disease.
Li L; Chen L; Zang J; Tang X; Liu Y; Zhang J; Bai L; Yin Q; Lu Y; Cheng J; Fu P; Liu F
Metabolism; 2015 May; 64(5):597-610. PubMed ID: 25682062
[TBL] [Abstract][Full Text] [Related]
3. Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility.
Tan SM; Ziemann M; Thallas-Bonke V; Snelson M; Kumar V; Laskowski A; Nguyen TV; Huynh K; Clarke MV; Libianto R; Baker ST; Skene A; Power DA; MacIsaac RJ; Henstridge DC; Wetsel RA; El-Osta A; Meikle PJ; Wilson SG; Forbes JM; Cooper ME; Ekinci EI; Woodruff TM; Coughlan MT
Diabetes; 2020 Jan; 69(1):83-98. PubMed ID: 31624141
[TBL] [Abstract][Full Text] [Related]
4. Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells.
Zitman-Gal T; Einbinder Y; Ohana M; Katzav A; Kartawy A; Benchetrit S
J Diabetes; 2019 Aug; 11(8):656-664. PubMed ID: 30575282
[TBL] [Abstract][Full Text] [Related]
5. Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy.
Yiu WH; Li RX; Wong DWL; Wu HJ; Chan KW; Chan LYY; Leung JCK; Lai KN; Sacks SH; Zhou W; Tang SCW
Nephrol Dial Transplant; 2018 Aug; 33(8):1323-1332. PubMed ID: 29294056
[TBL] [Abstract][Full Text] [Related]
6. Gene Regulatory Effect of Pyruvate Kinase M2 is Involved in Renal Inflammation in Type 2 Diabetic Nephropathy.
Li L; Tang L; Yang X; Chen R; Zhang Z; Leng Y; Chen AF
Exp Clin Endocrinol Diabetes; 2020 Sep; 128(9):599-606. PubMed ID: 31958846
[TBL] [Abstract][Full Text] [Related]
7. Allograft inflammatory factor-1 enhances inflammation and oxidative stress via the NF-κB pathway in diabetic kidney disease.
Fu Y; Wang X; Zhang L; Ren Y; Hao L
Biochem Biophys Res Commun; 2022 Jul; 614():63-69. PubMed ID: 35569377
[TBL] [Abstract][Full Text] [Related]
8. C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.
Lei YC; Lu CL; Chen L; Ge K; Yang LL; Li W; Wu YH
World J Gastroenterol; 2016 Dec; 22(46):10148-10157. PubMed ID: 28028363
[TBL] [Abstract][Full Text] [Related]
9. Endothelial CXCR2 deficiency attenuates renal inflammation and glycocalyx shedding through NF-κB signaling in diabetic kidney disease.
Cui S; Chen X; Li J; Wang W; Meng D; Zhu S; Shen S
Cell Commun Signal; 2024 Mar; 22(1):191. PubMed ID: 38528533
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol improves diabetic kidney disease by modulating the gut microbiota-short chain fatty acids axis in
Yan H; Zhang Y; Lin X; Huang J; Zhang F; Chen C; Ren H; Zheng S; Yang J; Hui S
Int J Food Sci Nutr; 2024 May; 75(3):264-276. PubMed ID: 38238900
[TBL] [Abstract][Full Text] [Related]
11. The Role of the Gut Microbiome in Diabetes and Obesity-Related Kidney Disease.
Zaky A; Glastras SJ; Wong MYW; Pollock CA; Saad S
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502562
[TBL] [Abstract][Full Text] [Related]
12. miR-223-3p mediates the diabetic kidney disease progression by targeting IL6ST/STAT3 pathway.
Tang P; Xu Y; Zhang J; Nan J; Zhong R; Luo J; Xu D; Shi S; Zhang L
Biochem Biophys Res Commun; 2023 Mar; 648():50-58. PubMed ID: 36731227
[TBL] [Abstract][Full Text] [Related]
13. The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.
Tao P; Ji J; Wang Q; Cui M; Cao M; Xu Y
Front Immunol; 2022; 13():1080456. PubMed ID: 36601125
[TBL] [Abstract][Full Text] [Related]
14. Complement C5 mediates experimental tubulointerstitial fibrosis.
Boor P; Konieczny A; Villa L; Schult AL; Bücher E; Rong S; Kunter U; van Roeyen CR; Polakowski T; Hawlisch H; Hillebrandt S; Lammert F; Eitner F; Floege J; Ostendorf T
J Am Soc Nephrol; 2007 May; 18(5):1508-15. PubMed ID: 17389734
[TBL] [Abstract][Full Text] [Related]
15. The change of gut microbiota-derived short-chain fatty acids in diabetic kidney disease.
Zhong C; Dai Z; Chai L; Wu L; Li J; Guo W; Zhang J; Zhang Q; Xue C; Lin H; Luo Q; Cai K
J Clin Lab Anal; 2021 Dec; 35(12):e24062. PubMed ID: 34689373
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Potential of Targeting Complement C5a Receptors in Diabetic Kidney Disease.
Trambas IA; Coughlan MT; Tan SM
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240105
[TBL] [Abstract][Full Text] [Related]
17. Micheliolide ameliorates diabetic kidney disease by inhibiting Mtdh-mediated renal inflammation in type 2 diabetic db/db mice.
Liu W; Chen X; Wang Y; Chen Y; Chen S; Gong W; Chen T; Sun L; Zheng C; Yin B; Li S; Luo C; Huang Q; Xiao J; Xu Z; Peng F; Long H
Pharmacol Res; 2019 Dec; 150():104506. PubMed ID: 31669149
[TBL] [Abstract][Full Text] [Related]
18. Sodium glucose co-transporter 2 (SGLT2) inhibition via dapagliflozin improves diabetic kidney disease (DKD) over time associatied with increasing effect on the gut microbiota in db/db mice.
Wu J; Chen Y; Yang H; Gu L; Ni Z; Mou S; Shen J; Che X
Front Endocrinol (Lausanne); 2023; 14():1026040. PubMed ID: 36777358
[TBL] [Abstract][Full Text] [Related]
19. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
[TBL] [Abstract][Full Text] [Related]
20. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils.
de Vries B; Köhl J; Leclercq WK; Wolfs TG; van Bijnen AA; Heeringa P; Buurman WA
J Immunol; 2003 Apr; 170(7):3883-9. PubMed ID: 12646657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
